Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Patent
1989-03-28
1990-08-14
Lipovsky, Joseph A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
A61K 3159
Patent
active
049487892
ABSTRACT:
Vitamin D.sub.3 derivatives of formula (I): ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3, which may be the same or different, each represent a hydrogen atom or a hydroxyl group; R.sub.4 is hydrogen or a C.sub.4-6 alkyl group that is optionally substituted by a hydroxyl group; preferably 22-oxa-1,25-(OJ).sub.2 D.sub.3, or OCT, are administered to treat hyperparathyroidism, particularly secondary hyperparathyroidism, without inducing hypercalcemia. The derivatives may be administered orally or parenterally. They are preferably administered intravenously in the course of renal dialysis.
REFERENCES:
Rollinson et al., "Mineral Nutrients", in Kirk-Othmer Encyclopedia of Chemical Technology, 3rd Edition, John Wiley & Sons, New York, vol. 15, p. 585, (1981).
Reiss et al., "Experience with a Radioimmunoassay of Parathyroid Hormone in Human Sera", Trans. Assoc. Am. Physicians, 81:104-115, (1968).
Arnaud, Claude D., "Hyperparathyroidism and Renal Failure", Kidney International, 4:89-95, (1973).
Slatopolsky et al., "Marked Suppression of Secondary Hyperparathyroidism by Intravenous Administration of 1,25-Dihydroxycholecalciferol in Uremic Patients", J. Clin. Invest., 74:2136-2143, (1984).
Brown et al., "Abnormal Regulation of Parathyroid Hormone Release by Calcium in Secondary Hyperparathyroidism due to Chronic Renal Failure", J. Clin. Endocrinol. Metab., 54:172-179, (1982).
Chertow, et al., "Decrease in Serum Immunoreactive Parathyroid Hormone in Rats and in Parathyroid Hormone Secretion", J. Clin. Invest., 72:668-678, (1975).
Cantley et al., "1,25-Dihydroxyvitamin D.sub.3 Suppresses Parathyroid Hormone Secretion from Bovine Parathyroid Cells in Tissue Culture", Endocrinology, 117:2114-2119, (1985).
Chan et al., "The Effect of 1,2 Dihydroxycholecalciferol on Parathyroid Hormone Secretion by Monolayer Cultures of Bovine Parathyroid Cells", Calcif. Tissue Int., 38:27-32, (1986).
Silver et al., "Regulation by Vitamin D Metabolites of Messenger Ribonucleic Acid for Preproparathyroid Hormone in Isolated Bovine Parathyroid Cells", Proc. Natl. Acad. Sci. U.S.A., 82:4270-4273, (1985).
Russell et al., "Suppression by 1,25(OH).sub.2 D.sub.3 of Transcription of the Pre-Proparathyroid Hormone Gene", Endocrinology, 119:2864-2866, (1986).
Silver et al., "Regulation by Vitamin D Metabolites of Parathyroid Hormone Gene Transcription in vivo in the Rat", J. Clin. Invest., 78:1296-1301, (1986).
Ostrem et al., "24- and 26-homo-1,25-dihydroxyvitamin D.sub.3 : Preferential Activity in Inducing Differentiation of Human Leukemia Cells HL-60 in vitro", Proc. Natl. Acad. Sci. U.S.A., 84:2610-2614, (1987).
Binderup et al., "Effects of Novel Vitamin D Analogue MC 903 on Cell Proliferation and Differentiation in vitro and on Calcium Metabolism in vivo", Biochemical Pharmacology, 37:889-895, (1988).
Abe et al., "Synthetic Analogues of Vitamin D.sub.3 with an Oxygen Atom in the Side Chain Skeleton", FEBS Lett., 226:58-62, (1987).
Murayama et al., "Synthetic Studies of Vitamin D.sub.3 Analogues, VIII. Synthesis of 22-Oxavitamin D.sub.3 Analogues", Chem. Pharm. Bull., 34:4410-4413, (1986).
Hughes, et al., "Regulation of Serum 1.alpha.,25-Dihydroxyvitamin D.sub.3 by Calcium and Phosphate in the Rat", Science, 190:578-580, (1975).
Garabedian et al., "Control of 25-Hydroxycholecalciferol Metabolism by Parathyroid Glands", Proc. Nat. Acad. Sci. U.S.A., 69:1673-1676, (1972).
Salusky et al., "High-Dose Calcitriol for Control of Renal Osteodystrophy in Children on CAPD", Kidney Int., 2:89-95, (1987).
Prior et al., "Experience with 1,25-Dihydroxycholecalciferol Therapy in Undergoing Hemodialysis Patients with Progressive Vitamin D.sub.2 -Treated Osteodystrophy", The Amer. Jour. of Med., 67:583-589, (1979).
Berl et al., "1,25 Dihydroxycholecalciferol Effects in Chronic Dialysis-a Double-Blind Controlled Study", Annals of Internal Medicine, 88:774-780, (1978).
Chugai Seiyaku Kabushiki Kaisha
Lipovsky Joseph A.
LandOfFree
Suppression of parathyroid hormone synthesis and secretion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Suppression of parathyroid hormone synthesis and secretion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Suppression of parathyroid hormone synthesis and secretion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-463134